{"result": "(\"entity\"<|>MARTÍN CUESTA HERNÁNDEZ<|>PERSON<|>Martín Cuesta Hernández is a licensed physician and doctor in medicine, specializing in Endocrinology and Nutrition, currently working at Hospital Clínico San Carlos in Madrid.)\n##\n(\"entity\"<|>HOSPITAL CLÍNICO SAN CARLOS<|>ORGANIZATION<|>Hospital Clínico San Carlos is a medical institution in Madrid where Martín Cuesta Hernández works as an endocrinologist.)\n##\n(\"entity\"<|>UNIVERSIDAD AUTÓNOMA DE MADRID<|>ORGANIZATION<|>Universidad Autónoma de Madrid is the university where Martín Cuesta Hernández obtained his medical degree in 2009.)\n##\n(\"entity\"<|>BEAUMONT HOSPITAL<|>ORGANIZATION<|>Beaumont Hospital in Dublin, Ireland, where Martín Cuesta Hernández worked as a Research Registrar in Endocrinology.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE DIABETES<|>ORGANIZATION<|>Sociedad Española de Diabetes is a professional society in Spain focused on diabetes research and treatment, of which Martín Cuesta Hernández is a member.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE MEDICINA INTERNA<|>ORGANIZATION<|>Sociedad Española de Medicina Interna is a medical society in Spain that published the referenced protocols on hypertriglyceridemia.)\n##\n(\"entity\"<|>HIPERTRIGLICERIDEMIA<|>EVENT<|>Hipertrigliceridemia refers to a medical condition characterized by elevated triglyceride levels in the blood, which can lead to pancreatitis.)\n##\n(\"entity\"<|>PANCREATITIS<|>EVENT<|>Pancreatitis is an inflammation of the pancreas that can occur due to high triglyceride levels and requires immediate medical attention.)\n##\n(\"relationship\"<|>MARTÍN CUESTA HERNÁNDEZ<|>HOSPITAL CLÍNICO SAN CARLOS<|>Martín Cuesta Hernández works as an endocrinologist at Hospital Clínico San Carlos in Madrid.<|>9)\n##\n(\"relationship\"<|>MARTÍN CUESTA HERNÁNDEZ<|>UNIVERSIDAD AUTÓNOMA DE MADRID<|>Martín Cuesta Hernández obtained his medical degree from Universidad Autónoma de Madrid in 2009.<|>7)\n##\n(\"relationship\"<|>MARTÍN CUESTA HERNÁNDEZ<|>BEAUMONT HOSPITAL<|>Martín Cuesta Hernández worked as a Research Registrar in Endocrinology at Beaumont Hospital in Dublin, Ireland.<|>6)\n##\n(\"relationship\"<|>MARTÍN CUESTA HERNÁNDEZ<|>SOCIEDAD ESPAÑOLA DE DIABETES<|>Martín Cuesta Hernández is a member of the Sociedad Española de Diabetes, contributing to diabetes research and technology.<|>5)\n##\n(\"relationship\"<|>MARTÍN CUESTA HERNÁNDEZ<|>SOCIEDAD ESPAÑOLA DE MEDICINA INTERNA<|>Martín Cuesta Hernández's work is referenced in the protocols published by the Sociedad Española de Medicina Interna.<|>4)\n##\n(\"relationship\"<|>HIPERTRIGLICERIDEMIA<|>PANCREATITIS<|>Hipertrigliceridemia can lead to pancreatitis if triglyceride levels are not managed properly.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: que es mayor de 1.000 mg/dl, la disminución de los triglicéridos debe llevarse sin retraso para prevenir la pancreatitis. Por ello, además de iniciar las medidas de hábitos de vida, han de prescribirse fármacos para disminuir los triglicéridos. Los fibratos, solos o asociados a ácidos grasos ω-3 o a ácido nicotínico son los fármacos de primera elección. En los pacientes con hepatopatía, insuficiencia renal o con contraindicaciones para el uso de fibratos, los ácidos grasos ω-3 en dosis de 2-4 g al día constituyen el tratamiento de primera elección por carecer de toxicidad sistémica. Las estatinas pueden utilizarse en la hipertrigliceridemia grave; sin embargo, se consideran de segunda elección debido a que en la mayoría de los casos el descenso de los triglicéridos que producen es moderado y de menor magnitud que el conseguido con los fármacos antes mencionados.\n---\nEn los pacientes con hipertrigliceridemia grave en los que exista una sospecha firme o se haya iniciado ya una pancreatitis aguda, la plasmaféresis inespecífica puede provocar una rápida normalización o una disminución muy acusada de la concentración de triglicéridos. Debido a la gravedad de la pancreatitis, y aunque la experiencia clínica es aún limitada, en estos pacientes ha de considerarse la plasmaféresis.\n\nReferencias:\n• Protocolos hipertrigliceridemias. CAPÍTULO III. Hipertrigliceridemias primarias. Síndrome de quilomicronemia. En: Pintó Sala X, coord. Madrid: Sociedad Española de Medicina Interna; 2008. p. 62.\n\n| MÓDULO | Obesidad, lípidos y trastornos electrolíticos |\n|---------|---------------------------------------------|\n| 8       | Trastornos electrolíticos                   |\n\n## AUTOR\n\nMartín Cuesta Hernández\n\n- Licenciado en Medicina en 2009 por la Universidad Autónoma de Madrid y doctor en Medicina en 2018 por la Universidad Royal College of Surgeons in Ireland. Realizó la especialidad en Endocrinología y Nutrición en el Hospital Clínico San Carlos de Madrid.\n\n- Ha trabajado como Research Registrar in Endocrinology tras finalizar la residencia en el Beaumont Hospital de Dublín, Irlanda. Desde 2016 trabaja como adjunto de Endocrinología en el Hospital Clínico San Carlos de Madrid en el área de diabetes y nuevas tecnologías. Sus áreas de investigación principales son diabetes tipo 1 y el hiperaldosteronismo primario.\n\n- Es miembro de los grupos de trabajo de Tecnología aplicada a la Diabetes, de la Sociedad Española de Diabetes, y de los grupos de suprarrenales y neuroendocrinología de la Sociedad Española de Endocrinología.\n---\n## 8.5 Trastornos electrolíticos\n\n### 46. Mujer de 62 años que acude a urgencias con disminución del nivel de conciencia, hiponatremia de 130 mEq/l, potasemia de 4,6 mEq/l, cloro de 100 mEq/l, bicarbonato sérico de 18 mEq/l, urea de 67 mg/dl y creatinina de 2 mg dl. El tratamiento a instaurar es:\n\nA. Suero salino isotónico e insulina.\nB. Suero salino isotónico, bicarbonato e insulina.\nC. Suero salino hipotónico, bicarbonato e insulina.\nD. Suero salino hipotónico e insulina.\n\n#### COMENTARIO\n\nSe trata de una pregunta sobre el tratamiento de una descompensación hiperglucémica con insuficiencia renal aguda. El tratamiento con insulina aparece como respuesta en las cuatro opciones, por lo que es de presuponer que presenta hiperglucemia asociada, con pseudohiponatremia asociada (disminución de 1,6 mmol/l de sodio plasmático por cada 100 mg/dl de elevación de la glucemia plasmática de media). El uso de insulina fuera de la hiperglucemia podría darse en el contexto de tratamiento de una hiperpotasemia que la paciente no presenta, por lo que el cuadro se debe a una hiperglucemia marcada con pseudohiponatremia e insuficiencia renal aguda.\n\nEl tratamiento debe realizarse con suero salino isotónico, puesto que solo en el caso de deshidratación leve con hipernatremia o normonatremia corregida a glucemia se debe utilizar suero hipotónico al 0,45%. En este caso concreto, la presencia de insuficiencia renal indica hipovolemia marcada, siendo indicación de suero salino isotónico. Es el suero isotónico el que se debe utilizar en caso de hipovolemia marcada o shock, ya que perfunde de manera más eficaz el riñón y órganos críticos (cerebro y corazón) que el suero hipotónico (el\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}